PRGO — Perrigo Company plc

Is PRGO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of November 17, 2026

Perrigo Company plc (PRGO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $16.18. The rating moved from Overbought to Neutral on November 17, 2026.

AI analysis

Perrigo Company plc (PRGO) is a defensive consumer healthcare and private-label manufacturer with steady cash generation and durable retail relationships. Near-term performance will be governed by margin management (input costs and pricing), execution on cost-savings and any bolt-on M&A, while growth is likely to remain modest in developed markets with upside coming from international expansion or successful new product rollouts. Macro caution and sector flows into staples provide relative support, but customer concentration, supply-chain disruption and regulatory/quality risks are material near-term concerns.

Key factors

  • Broad consumer healthcare portfolio with stable, defensive demand that tends to hold up in risk-off environments
  • Scale in private-label manufacturing and established retail/customer relationships that support recurring revenue
  • Mixed growth profile: limited organic growth in saturated developed markets offset by pockets of international expansion and potential M&A
  • Margin sensitivity to input-cost inflation, freight/capacity constraints and pricing pressure from large retail customers
  • Currency exposure and capital allocation history (debt repayment / opportunistic acquisitions) that shapes near-term cash flow flexibility
  • Sector-wide defensive flows into consumer healthcare/pharma support relative downside in volatile sessions

Risks

  • Customer concentration: heavy reliance on large retail chains/private-label contracts could compress pricing and volumes if renegotiated
  • Input-cost inflation or supply-chain disruption that compresses gross margins if not fully passed through
  • Slower-than-expected organic growth in core OTC categories and delayed benefit realization from any recent acquisitions or cost-savings
  • Regulatory, quality or product-safety issues (recalls, compliance) that could drive reputational and financial costs
  • Currency volatility and interest-rate driven refinancing costs that could weigh on reported results and free cash flow
  • Competitive pressure from branded multinationals and lower-cost generic/contract manufacturers limiting pricing power

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PRGO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.